For diabetes management, if HbA1c remains above target despite maximal tirzepatide dosing, combination therapy with metformin, SGLT2 inhibitors, or basal insulin should be considered based on individual patient factors and contraindications
The Lancet
In theory and clinical observation, this may: Enhance appetite regulation Provide additional metabolic support Influence how the body stores and uses energy However, response varies between individuals, and treatment should always be personalized
It helps with weight loss by making you feel less hungry and helping the body lose fat
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial